Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.
AstraZeneca’s revival has continued with a third successive quarter of growth, as sales of new drugs for cancer and lung diseases outperformed the market’s expectations.
Boehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, as price competition began to affect its biggest selling drug Spiriva.<
